AO-176 is an IgG2 CD47 targeted antibody, which blocks the “don’t eat me” signal enabled by CD47’s interaction with SIRPa and induces phagocytosis. In addition;
These features of AO-176 offer a highly differentiated profile.
We target CD47 differently, and given our lead therapy’s potential, we plan to develop AO-176 broadly. Backed by preclinical research and encouraging early clinical tolerability and activity, we are advancing AO-176 in Phase 1/2 clinical trials for patients with select solid tumors and hematologic malignancies.